Bioventix PLC (LON:BVXP - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 2,734.67 ($37.53) and traded as low as GBX 2,600 ($35.68). Bioventix shares last traded at GBX 2,700 ($37.05), with a volume of 1,989 shares trading hands.
Bioventix Stock Performance
The firm has a market cap of £145.57 million, a price-to-earnings ratio of 17.98 and a beta of 0.35. The company's fifty day moving average is GBX 2,748.41 and its two-hundred day moving average is GBX 2,872.94.
Bioventix (LON:BVXP - Get Free Report) last posted its earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.99) earnings per share for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. As a group, analysts forecast that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.
Bioventix Cuts Dividend
The firm also recently announced a dividend, which was paid on Friday, April 25th. Investors of record on Thursday, April 10th were issued a dividend of GBX 70 ($0.96) per share. The ex-dividend date of this dividend was Thursday, April 10th. This represents a dividend yield of 2.95%. Bioventix's payout ratio is 102.19%.
Insider Activity at Bioventix
In other news, insider Bruce Hiscock purchased 31 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were purchased at an average price of GBX 2,632 ($36.12) per share, with a total value of £815.92 ($1,119.69). Company insiders own 8.02% of the company's stock.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Further Reading
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
